Loading company…
Tr1x develops engineered T-cell therapies for autoimmune and inflammatory diseases.
Founded in 2018 by Professor Maria Grazia Roncarolo, Tr1x is based in San Diego, US, and develops cellular therapies intended to induce immune tolerance and restore homeostasis. Its platform supports scalable production of engineered T cells for people with serious diseases. In January 2024, the company raised USD 75 million in series A funding led by The Column Group, with participation from Neva and Alexandria Venture Investments.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in